Supernus Pharmaceuticals
SUPN
244 hedge funds and large institutions have $1.56B invested in Supernus Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 87 increasing their positions, 80 reducing their positions, and 34 closing their positions.
267% more call options, than puts
Call options by funds: $1.29M | Put options by funds: $352K
2.65% more ownership
Funds ownership: 103.59% → 106.23% (+2.6%)
9% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 80
6% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 34
2% less funds holding
Funds holding: 250 → 244 (-6)
19% less capital invested
Capital invested by funds: $1.93B → $1.56B (-$370M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$49.3M |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$39.1M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$11.4M |
| 4 |
Renaissance Technologies
New York
|
+$10.2M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$8.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$44M |
| 2 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
-$29.7M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
-$12.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$11.5M |
| 5 |
CWM
Congress Wealth Management
Boston,
Massachusetts
|
-$6.06M |
SUPN Hedge Fund Activity: Q2 2024 in Review
244 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q2 2024, worth a combined $1.56B — down 19% from $1.93B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of SUPN and 32 opened new positions — a net loss of 2 holders — while 80 trimmed existing stakes and 87 added.
The largest buyer was Armistice Capital, adding an estimated $49.3M. The largest seller was Woodline Partners, exiting entirely with an estimated $44M sold.
- 244 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q2 2024, down from 250 in Q1 2024.
- Funds reported $1.56B of Supernus Pharmaceuticals stock for Q2 2024, down 19% quarter-over-quarter.
- 32 funds opened new Supernus Pharmaceuticals positions in Q2 2024 and 34 closed out, a net change of -2 holders.
- The largest Supernus Pharmaceuticals buyer in Q2 2024 was Armistice Capital, an estimated $49.3M added.
- The largest Supernus Pharmaceuticals seller in Q2 2024 was Woodline Partners, an estimated $44M sold.
Based on aggregated 13F filings for Q2 2024.